Inclusion Criteria:

Histology and staging of the disease

- Histological confirmed NSCLC; histology may include: large cell, squamous cell or
adenocarcinoma but no SCLC.

- Anatomically and functionally resectable NSCLC stage IB (T2N0) stage II (T1-2 N1, T3
N0) or stage IIIA (T3 N1) (see TAKO guidelines 2006, www.tako.or.at)

- Measurable disease according to RECIST criteria

General conditions

- 18-80 years.

- WHO 0-2; life expectancy of more than 3 months

- Effective contraception for both male and female patients if the risk of conception
exists

- Adequate respiratory function, sufficient for necessary surgical treatment

- Adequate hematological function (Hb > 10 g/dl, ANC > 2.0 x 10 9/L, platelets > 100 x
10 9/L).

- Adequate renal and hepatic functions: total bilirubin within normal limits, serum
creatinine within normal limits, in case of limit value the creatinine clearance
should be > 60 ml/min, ASAT and ALAT < 2.5 x UNL, alkaline phosphatase < 5 x UNL.

Initial work-up

- Complete initial work-up within three weeks prior to first infusion includes chest CT
scan, abdominal CT-scan, brain CT scan if indicated, PET-scan, bronchoscopy and
mediastinoscopy, pulmonary function. Within 7 days prior to inclusion laboratory
investigations and biological work up.

- Signed initial consent prior to protocol specific procedures.

Exclusion Criteria:

Diagnosis

- Evidence of brain metastases or other distant metastasis equivalent to stage IV
disease

- History of prior malignancies, except for curatively treated non-melanoma skin cancer
or in situ carcinoma of the cervix or other curatively treated cancer with no
evidence of disease for at least five years

- Other serious concomitant illness or medical condition:

- Congestive heart failure or angina pectoris, except if medically controlled, history
of myocardial infarction within 1 year from study entry, uncontrolled hypertension or
arrhythmia

- History of significant neurological or psychiatric disorders, including dementia or
seizure

- Active infection requiring i.v. antibiotics

- Active ulcer, unstable diabetes mellitus or other contraindications to corticotherapy

- Current peripheral neuropathy WHO grade > 2

Prior or concurrent therapy

- Prior chemotherapy or immunotherapy for NSCLC

- Prior surgery or radiotherapy for NSCLC

- Concurrent treatment with other experimental drugs, unapproved medical procedures or
other anticancer therapy

- Concurrent continuous treatment with systemic steroids for antiemetic use,
intermittent application is allowed

General conditions

- Pregnant (absence to be confirmed by ß-HCG-test) or lactating patients

- Patients (M/F) with reproductive potential not implementing adequate contraceptive
measurements

- Participation in other clinical trials with experimental agents or non approved
medical procedures during study and within 30 days prior to study entry

- Psychological, familial, sociological or geographical conditions which do not permit
medical follow-up and compliance with the study protocol.